Differential risk of Alzheimer's disease in MCI subjects with elevated Abeta

被引:0
|
作者
Zhou, Bin [1 ]
Fukushima, Masanori [1 ]
机构
[1] Fdn Learning Hlth Soc Inst, 8F,Nagoya Mitsui Bussan Bldg,1-16-21 Miekiminami,N, Nagoya, Aichi 4500003, Japan
关键词
Mild cognitive impariment; Alzheimer's disease; PET beta amyloid; Risk assessment; PROTEINS;
D O I
10.1016/j.jns.2024.123319
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Backgrounds: People with elevated beta amyloid have different risk and progress speed to Alzheimer's disease. Purpose: The research is to validate the risk classification of AD developed in the Shanghai mild cognitive impairment (MCI) cohort study using ADNI data. Methods: The risk classification of AD in MCI was based on several optimal cut-off points of a novel parameter Cog_Vol. Results: In total, 843 subjects with MCI were included, of whom 220 had elevated PET beta amyloid. 273 (32.3 %) and 70 (31.8 %) progressed to AD in all subjects and in those with elevated PET beta amyloid, respectively. The risk of AD in subjects whose Cog_Vol >340 was very low, while the risk for those with Cog_Vol less than 101 indicated a super high within 4 years of follow-up. Discussion: Risk classification using Cog_Vol at an optimal value was able to detect subjects among those with PET-amyloid-elevated MCI were at greater risk of developing AD and were unlikely to develop AD within 4 years of follow-up.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Structural studies of Alzheimer's disease Abeta peptide oligomers
    Jablonowska, A
    Bakun, M
    Dadlez, M
    JOURNAL OF NEUROCHEMISTRY, 2003, 85 : 22 - 22
  • [22] Abeta-Responsive Cells as a Therapy in Alzheimer's Disease
    Spetz, Madeline R.
    Conger, Dylan J.
    Kim, Hyosung
    Schrag, Matthew S.
    Lippmann, Ethan S.
    Brunger, Jonathan M.
    MOLECULAR THERAPY, 2024, 32 (04) : 198 - 198
  • [23] Degradation of Abeta peptide by endopeptidases: Role in Alzheimer's disease
    Kindy, M
    Hersh, L
    Yu, J
    Zhu, H
    Mukherjee, A
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S185 - S185
  • [24] CSF Abeta38, Abeta40 and Abeta42 levels in Alzheimer's disease patients and controls
    Schoonenboom, NS
    Scheltens, P
    Van Kamp, GJ
    Mehta, PD
    NEUROBIOLOGY OF AGING, 2004, 25 : S147 - S147
  • [25] Risk factors and differential diagnosis of Alzheimer’s disease
    F. Müller-Spahn
    C. Hock
    European Archives of Psychiatry and Clinical Neuroscience, 1999, 249 (Suppl 3) : S37 - S42
  • [26] Risk factors and differential diagnosis of Alzheimer's disease
    Müller-Spahn, F
    Hock, C
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1999, 249 : 37 - 42
  • [27] Differential diagnosis of MCI with Lewy bodies and MCI due to Alzheimer’s disease by visual assessment of occipital hypoperfusion on SPECT images
    Takashi Nakata
    Kenichi Shimada
    Akiko Iba
    Haruhiko Oda
    Akira Terashima
    Yutaka Koide
    Ryota Kawasaki
    Takahiro Yamada
    Kazunari Ishii
    Japanese Journal of Radiology, 2024, 42 : 308 - 318
  • [28] Differential diagnosis of MCI with Lewy bodies and MCI due to Alzheimer's disease by visual assessment of occipital hypoperfusion on SPECT images
    Nakata, Takashi
    Shimada, Kenichi
    Iba, Akiko
    Oda, Haruhiko
    Terashima, Akira
    Koide, Yutaka
    Kawasaki, Ryota
    Yamada, Takahiro
    Ishii, Kazunari
    JAPANESE JOURNAL OF RADIOLOGY, 2024, 42 (03) : 308 - 318
  • [29] Abeta predictor of Alzheimer disease symptoms
    Sephton, Chantelle F.
    Yu, Gang
    ARCHIVES OF NEUROLOGY, 2008, 65 (07) : 875 - 876
  • [30] An attentional task in subjects at genetic risk for Alzheimer's disease
    Burggren, A
    Small, G
    Sabb, F
    Bookheimer, SY
    NEUROIMAGE, 2001, 13 (06) : S643 - S643